

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Starpharma Holdings Limited
ABN	20 078 532 180

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Jacinth K Fairley
Date of last notice	12 September 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	1 October 2022
No. of securities held prior to change	<ol style="list-style-type: none"> 1. 3,252,386 Ordinary Shares (direct) 2. 698,048 Ordinary Shares (indirect) Fairley Family Super Fund Pty Ltd 3. 55,000 Ordinary Shares (indirect) Dr Ian Fraser 4. 5,502,890 Performance Rights (SPLAK)
Class	Performance Rights
Number acquired	Nil
Number disposed	362,416 Performance Rights forfeited
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> 1. 3,252,386 Ordinary Shares (direct) 2. 698,048 Ordinary Shares (indirect) Fairley Family Super Fund Pty Ltd 3. 55,000 Ordinary Shares (indirect) Dr Ian Fraser 4. 5,140,474 Performance Rights (SPLAK)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Forfeiture of 332,814 Performance Rights for the three year performance period from 1 July 2019 to 30 June 2022, with a vesting date of 30 September 2022, as performance conditions were not met. Forfeiture of 29,602 Performance Rights for the one year performance period from 1 July 2021 to 30 June 2022, with a vesting date of 30 June 2023, as performance conditions were not met.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.